Literature DB >> 5109123

Cyclophosphamide and the bladder.

P H Worth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5109123      PMCID： PMC1800237          DOI： 10.1136/bmj.3.5767.182-a

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  6 in total

1.  Proceedings: The effect of immunosuppression on cancer.

Authors:  I Penn; T E Starzl
Journal:  Proc Natl Cancer Conf       Date:  1972

Review 2.  Problems with immunosuppressive agents in renal disease.

Authors:  J S Cameron
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1975

3.  Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma.

Authors:  Bjoern G Volkmer; Evelyn M Seidl-Schlick; Dietmar Bach; Imre Romics; Klaus Kleinschmidt
Journal:  Clin Rheumatol       Date:  2004-12-01       Impact factor: 2.980

4.  Bladder carcinoma following cyclophosphamide therapy. A case report.

Authors:  H Kiesswetter; N Baloch; J Flamm
Journal:  Int Urol Nephrol       Date:  1985       Impact factor: 2.370

Review 5.  Drug-induced bladder and urinary disorders. Incidence, prevention and management.

Authors:  M J Drake; P M Nixon; J P Crew
Journal:  Drug Saf       Date:  1998-07       Impact factor: 5.606

6.  Ifosfamide-Induced Malignancy of Ureter and Bladder.

Authors:  Aparna Sannu; Resmi Radha; Anitha Mathews; Rari Padmakumari Mony; Anil Prahladan; Francis V James
Journal:  Cureus       Date:  2017-08-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.